Shield Therapeutics Share Discussion Threads

[oapknob1] 24/6/2021 08:51

Patient uptake and sales figures from US will be the spark for any major rise if they are good.Take a pill or go into hospital for IV?Know what I would prefer personally.

[purchaseatthetop] 24/6/2021 08:51

The funds arrive over the next hours, days and weeks. The one certainty now is that they will arrive. This will be a huge dividend share.

[78steve] 24/6/2021 08:49

Probably see more buyers once 60p breaks convincingly hasnt quite done it as yet

[little minx] 24/6/2021 08:42

A few might be waiting for the presentation

[purchaseatthetop] 24/6/2021 08:42

Itstheoxman...in a few minutes. The traders have gone and now finally the funds will arrive looking at US cashflow and the leadership delivering it.

Porters Five Forces. Applied to STX makes the case. No threat of new entrants. No threat of substitution. Power of supplier STX monopoly. Power of buyer nil as alterative is IV which costs 10 times as much plus time, pain, boredom, infection.

That's why I bought anyway.

[its the oxman] 24/6/2021 08:33

Got to bust 60p , can't be long.

[babbler] 24/6/2021 08:18

Amazing. Vertu hard to buy yesterday and today they all sell off. More fool them.

[russ42] 24/6/2021 08:12

Mass sell off by the 5% brigade

[purchaseatthetop] 24/6/2021 08:11

Fozzie....traders who bought for he news. It was hardly mastermind to know the the launch was going to be announced today, even we worked it out. Easy 10% for news traders. In and out. It will drift down then finish well over 60p Imo.

[fozzie] 24/6/2021 08:09

Loads of small sells going through, bonkers!

[nico115] 24/6/2021 08:06

Huge upside here 150p for me

[babbler] 24/6/2021 08:01

As predicted. Lovely. Now smash that 60p down please.

[purchaseatthetop] 24/6/2021 08:01

78steve whatever drugs you are on can I have some please?

[78steve] 24/6/2021 07:52

Looks like management delivering on promises. to think this hit circa 200p when FDA news announced where to now with launch. 100p now? Appreciate dilution to factor in. Wouldnt be surprised to see a bit of red today but hopefully onwards and upwards

[fozzie] 24/6/2021 07:43

Obvious that news leaked into the market yesterday. The news should see the share price recapture recent highs but you never know .

[kalkaar] 24/6/2021 07:36

This has been a long time coming.. patience of a saint and a lot of pain endured..

Time for payback now..

They'll try and shake you and break you out of your position make no mistake but monumental moment finally arrives..

Time to sit back and enjoy the ride now..

GLAH

[smallfry1] 24/6/2021 07:24

Patt full respect Sir

[smallfry1] 24/6/2021 07:22

Thank you
Spot on Russ

[luisfrg] 24/6/2021 07:17

10% nailed on minimum

[best1467] 24/6/2021 07:16

I’m expecting double digit rise today for sure because it’s credibility to the new team

[david gruen] 24/6/2021 07:15

24/06/2021 7:00am
UK Regulatory (RNS & others)

Shield Therapeutics (LSE:STX)
Intraday Stock Chart

Thursday 24 June 2021

Click Here for more Shield Therapeutics Charts.
TIDMSTX

RNS Number : 9027C

Shield Therapeutics PLC

24 June 2021

Shield Therapeutics plc

("Shield" or the "Company" or the "Group")

US launch of Accrufer(R) confirmed for July 1, 2021

London, UK, June 24, 2021: Shield Therapeutics plc (LSE: STX), a commercial stage, pharmaceutical company with a focus on addressing iron deficiency with its lead product Feraccru(R)/Accrufer(R) (ferric maltol), confirms that, in line with prior guidance, it will launch Accrufer(R) in the US on July 1, 2021.

Launch stocks of Accrufer(R) are currently being distributed through the wholesaler channels and will be available to doctors and other prescribers in all parts of the US by July 1, 2021. A sales force including 30 sales representatives has been recruited and trained and will be starting to contact key prescribers during next week.

Greg Madison, CEO of Shield, said "We are pleased to make Accrufer(R) available to physicians and their patients in the US. Iron deficiency and iron deficiency anemia are significant challenges for millions of patients. Accrufer(R) represents a novel form of oral iron which offers clinical effectiveness while being well tolerated in clinical trials, and has the potential to be a significant advance for those patients in the US."

[best1467] 24/6/2021 07:14

Yes great news like the comment all parts of the U/S onwards and upwards from this point

[nobbygnome] 24/6/2021 07:13

Good to see the launch more or less on schedule. Not sure it will rise a lot today but let's hope. The company has evolved a long way from when they were trying to sign a deal around 2 years ago and surely the only way is up now. How high depends on how good the sales are. Once the drug is established there has to be a good chance of a takeover and this is the most likely endgame IMHO.